# A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

> **NCT03534947** · PHASE2 · COMPLETED · sponsor: **Melanoma Institute Australia** · enrollment: 16 (actual)

## Conditions studied

- Basal Cell Carcinoma
- Basal Cell Carcinoma of Skin, Site Unspecified
- Skin Cancer
- Invasive Carcinoma

## Interventions

- **DRUG:** Sonidegib
- **DRUG:** Imiquimod
- **PROCEDURE:** Surgery
- **OTHER:** Best supportive care

## Key facts

- **NCT ID:** NCT03534947
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03534947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03534947, "A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03534947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*